E2F5 as an independent prognostic factor in esophageal squamous cell carcinoma

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5415-5420

  Ishimoto, Takeshi ^a   Shiozaki, Atsushi ^a   Ichikawa, Daisuke ^a   Fujiwara, Hitoshi ^a   Konishi, Hirotaka ^a   Komatsu, Shuhei ^a   Kubota, Takeshi ^a   Okamoto, Kazuma ^a   Nakashima, Shingo ^a   Shimizu, Hiroki ^a   Nako, Yoshito ^a   Kishimoto, Mitsuo ^a   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Cell proliferation; E2F5; Esophageal squamous cell carcinoma

Indexed keywords

KI 67 ANTIGEN; TRANSCRIPTION FACTOR E2F5;

ADULT; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR INVASION;

EID: 84891418698     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, Negri E and La Vecchia C: Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 122: 1118-1129, 2008.
2. Lepage C, Rachet B, Jooste V, Faivre J and Coleman MP: Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 103: 2694-2699, 2008.
3. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB Jr., Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL and Roth JA: Treatment outcomes of resected esophageal cancer. Ann Surg 236: 376-384, 2002.
4. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 359: 1727-1733, 2002.
5. Dimova DK and Dyson NJ: The E2F network: Old acquaintances with few faces. Oncogene 24: 2810-2826, 2005.
6. Wan Z, Zhi N, Wong S, Keyvanfar K, Liu D, Raghavachari N, Munson PJ, Su S, Malide D, Kajigaya S and Young NS: Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors. J Clin Invest 120: 3530-3544, 2010.
7. Cao L, Peng B, Yao L, Zhang X, Sun K, Yang X and Yu L: The ancient function of RB-E2F pathway: Insights from its evolutionary history. Biol Direct 5: 55-75, 2010.
8. Eymin B, Gazzeri S, Brambilla C and Brambilla E: Distinct pattern of E2F1 expression in human lung tumours: E2F1 is up-regulated in small cell lung carcinoma. Oncogene 20: 1678-1687, 2001.
9. Cao L, Peng B, Yao L, Zhang X, Sun K, Yang X and Yu L: Clinical relevance of E2F family members in ovarian cancer-an evaluation in a training set of 77 patients. Clin Cancer Res 13: 144-151, 2007.
10. Kwon MJ, Nam ES, Cho SJ, Park HR, Shin HS, Park JH, Park CH and Lee WJ: E2F1 expression predicts outcome in Korean women who undergo surgery for breast carcinoma. Ann Surg Oncol 17: 564-571, 2010.
11. Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, Lee I, Sohn TS, Noh JH, Heo JS, Kim S, Lim do H, Kim KM and Kang WK: Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res 14: 82-88, 2008.
12. Chen HZ, Tsai SY and Leone G: Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev Cancer 9: 785-797, 2009.
13. Sardet C, Vidal M, Cobrinik D, Geng Y, Onufryk C, Chen A and Weinberg RA: E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle. Proc Natl Acad Sci USA 92: 2403-2407, 1995.
14. Classon M and Dyson N: p107 and p130: Versatile proteins with interesting pockets. Exp Cell Res 264: 135-147, 2001.
15. Umemura S, Shirane M, Takekoshi S, Kusakabe T, Itoh J, Egashira N, Tokuda Y, Mori K and Osamura YR: Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. Br J Cancer 100: 764-771, 2009.
16. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U and Werner M: Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med 85: 293-304, 2006.
17. Kothandaraman N, Bajic VB, Brendan PN, Huak CY, Keow PB, Razvi K, Salto-Tellez M and Choolani M: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer 10: 64, 2010.
18. Jiang Y, Yim SH, Xu HD, Jung SH, Yang SY, Hu HJ, Jung CK and Chung YJ: A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma. World J Gastroenterol 17: 470-477, 2011.
19. Fuchs B, Zhang K, Schabel A, Bolander ME and Sarkar G: Identification of twenty-two candidate markers for human osteogenic sarcoma. Gene 278: 245-252, 2001.
20. Sobin L, Gospodarowicz M, and Wittekind C (eds.): TNM Classification of Malignant Tumors. Seventh Edition. Hoboken: Wiley, 2009.
21. Kunisaki C, Makino H, Takagawa R, Yamamoto N, Nagano Y, Fujii S, Kosaka T, Ono HA, Otsuka Y, Akiyama H, Ichikawa Y and Shimada H: Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg 12: 802-810, 2008.
22. Ozawa S: Comprehensive registry of esophageal cancer in Japan, 2003. Esophagus 8: 9-29, 2011.
23. Nevins JR: E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424-429, 1992.
24. Apostolova MD, Ivanova IA, Dagnino C, D'Souza SJ and Dagnino L: Active nuclear import and export pathways regulate E2F-5 subcellular localization. J Biol Chem 277: 34471-34479, 2002.
25. Sasagawa H, Shiozaki A, Iitaka D, Ichikawa D, Komatsu S, Fujiwara H, Okamoto K, Nakashima S, Kinoshita O, Murayama Y, Kuriu Y, Ikoma H, Nakanishi M, Ochiai T, Kokuba Y and Otsuji E: Ki-67 labeling index as an independent prognostic factor in human esophageal squamous cell carcinoma. Esophagus 9: 195-202, 2012.